CN100339377C - Camptothecine derivative and its preparation - Google Patents
Camptothecine derivative and its preparation Download PDFInfo
- Publication number
- CN100339377C CN100339377C CNB2005100987438A CN200510098743A CN100339377C CN 100339377 C CN100339377 C CN 100339377C CN B2005100987438 A CNB2005100987438 A CN B2005100987438A CN 200510098743 A CN200510098743 A CN 200510098743A CN 100339377 C CN100339377 C CN 100339377C
- Authority
- CN
- China
- Prior art keywords
- camptothecine
- open loop
- group
- acid amides
- lactonic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides camptothecin derivatives represented by formula (1) and preparation thereof. In the formula, R1 represents 0 to 3 identical or different substituent radicals on one bit of 9, 10 and 11, and the substituent radicals comprise halogen atoms, hydroxy and alkoxyl; R2 represents straight chains of C2 to C5 or branched chains of alkylene; R3 represents hydrogen atoms or R4CO-, wherein R4 represents low-grade alkyl, low-grade alkamino alkyl or low-grade alkoxyl alkyl; Y represents heterocyclic basic radicals or hydrogenated heterocyclic basic radicals. The present invention also comprises a preparing method of each compound shown as the formula (1) and applications thereof in treating cancer.
Description
Technical field:
The present invention relates to a kind of novel derivative of new antitumour drug compounds, particularly a kind of camptothecine, their preparation and application.
Background technology:
Found in the compound of the E lactonic ring open loop of camptothecine some activity and camptothecine quite or better, novel derivative that toxicity is littler than camptothecine.The water soluble that wherein has, thereby be suitable for making injection etc. and use formulation more easily.For example, Japanese first drugmaker once used NH
2CH
2CH
2N (CH
3)
2E ring is carried out ring-opening reaction, and then the new compound of a series of E ring open loop that 17-hydroxyl acylations is obtained (referring to J.P.A, H1 131179; CN1126212A).Gondola Indena S.P.A. company makes the E ring open loop of camptothecine generate alkali metal carboxylate by alkaline hydrolysis, again with 17-hydroxyl acylations, also obtain a series of water soluble camptothecin novel derivatives (referring to US006,121,277A).But the anti-tumor activity of these camptothecine novel derivatives and low toxicity type are still not ideal enough.
The invention provides the new E ring opened loop compound that the end of the chain contains heterocyclic base or hydrogenation heterocyclic base, or further the hydroxyl on the 17-position of these opened loop compounds is carried out the compound of acidylate with different acylating reagents.These compounds are owing to contain heterocyclic base (imidazoles, pyridine, pyrimidine, pyrazine etc.) or hydrogenation heterocyclic base (piperidines, piperazine, morpholine etc.) and easy and HCl, CF on the end group
3COOH, RSO
3H etc. form soluble salt, and preparation is simple, and good water solubility, antitumour activity height, toxicity are little.
Summary of the invention:
The invention provides a kind of novel derivative of camptothecine, its chemical structure is as follows:
Wherein
R
1Represent 9,10 or the 11-position on 0-3 identical or different substituting group, these substituting groups are selected from halogen atom, hydroxyl, alkoxyl group; As: F, Cl, Br, OH, OMe, OEt etc.
R
2Represent C
2-C
5The straight or branched alkylidene group; As :-CH
2CH
2-,-CH
2CH
2CH
2-,-CH
2(CH
2)
2CH
2-,-CH
2CH (CH
3) CH
2-etc.R
3Represent hydrogen atom or R
4CO-,
R
4Represent low alkyl group, lower alkyl amino alkylidene group or lower alkoxy alkylidene group; As :-CH
3-CH
2CH
3,-(CH
2)
nCH
3,-(CH
2)
nOCH
3,-(CH
2)
nNHCH
3,-(CH
2)
nN (CH
3)
2Deng (n=1-3)
Y represents heterocyclic base or hydrogenation heterocyclic bases such as imidazoles, pyridine, pyrimidine, pyrazine, as piperidines, piperazine, morpholine.
Preferred compound is:
R
1Represent H, OH
R
2Representative-CH
2CH
2CH
2-
R
3Represent H, R
4CO
R
4Representative-CH
3,-CH
2CH
3,-(CH
2)
nNR
2
Y represents 1-imidazolyl, 1-morpholinyl
Most preferred is:
R
1Represent H
R
2Representative-CH
2CH
2CH
2-
R
3Represent H, R
4CO
R
4Representative-CH
3,-CH
2CH
3
Y represents 1-imidazolyl, 1-morpholinyl
The chemical name of most preferred is:
21-N[3-(1-morpholinyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=H, the Y=1-morpholinyl); 21-N[3-(1-morpholinyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
3, the Y=1-morpholinyl); 21-N[3-(1-morpholinyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
2CH
3, the Y=1-morpholinyl); 21-N[3-(1-imidazolyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=H, the Y=1-imidazolyl); 21-N[3-(1-imidazolyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
3, the Y=1-imidazolyl); 21-N[3-(1-imidazolyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
2CH
3, the Y=1-imidazolyl).
Compound of the present invention is the reagent N H that contains two basic groups with a series of
2-(CH
2)
n-Y (Y represents heterocyclic base or hydrogenation heterocyclic base) carries out to the E of camptothecine ring that ring-opening reaction obtains.
The preparation method is listed in the following reaction formula: wherein, the compound of formula (1) representative is by the camptothecine (CPT) of formula (2) definition, 10-hydroxyl CPT, 10 or crude substance such as 11-methoxyl group CPT or by semisynthetic 9,10,11-contains the substituent CPT derivative that defines in (1) formula and separates reagent ammonia through the ammonia of formula (3) definition and separate open loop on the position, or further the 17-hydroxy esterification is prepared, reaction formula is as follows:
R in the formula
1, R
2, R
3, R
4, Y definition cotype (1) compound.
The R of reaction formula below
2The compound of representing with Y is a most preferred of the present invention.
Though separating open loop reaction, ammonia also can adopt solubilizing agent not directly to separate the CPT derivative raw material reaction that reagent and formula (2) define with excess of ammonia.But because of the ammonia that uses among the present invention separate the reagent boiling point higher, should not remove excess of ammonia with the method for underpressure distillation and separate reagent, bring difficulty can for ensuing separation and purification of products, therefore adopt slightly excess of ammonia to separate reagent and in appropriate solvent, react with the raw material that formula (2) defines.After the reaction reaction mixture is poured in ether or sherwood oil or the mixed solvent of the two, made the product precipitation, the precipitation that leaches further gets product with column chromatography purification.
The esterification of open-loop products 17-position hydroxyl, available corresponding acylating agent carries out under pyridine, DCC or DMAP catalysis as acid anhydrides, acyl chlorides or other suitable acylating agent.
For example open-loop products and acid anhydrides can be spent the night at heated and stirred in the presence of pyridine, the gained reaction mixture is poured in the sherwood oil, and the yellow solid that leaches separates through silica gel column chromatography, obtains very pure acylate.
Various CPT novel derivatives that the present invention obtains and the various acid that wait the medicinal permission of mole, example hydrochloric acid, methylsulfonic acid or trifluoroacetic acid reaction can get various soluble salts.
The present invention also comprises the pharmaceutical preparation with camptothecin derivative preparation of the present invention, pharmaceutical preparation of the present invention comprises camptothecin derivative of the present invention or its physiologically acceptable salt of medicine effective quantity, also can add the medicine acceptable carrier in case of necessity, described preparation adopts the preparation of technology of pharmaceutics routine techniques, and preferred dosage form is the dosage form of the injection of unitary dose.
Following data by experiment illustrate beneficial effect of the present invention:
One, XY-8 is to the antitumor action of vitro culture human tumor cells
1. XY-8 anti tumor activity in vitro screening
1.1 tried thing
XY-8 (for the compound of the embodiment of the invention one preparation) Hefei ZhongKeDa Bioisystech Co., Ltd provides.Positive drug alkyl camptothecine injection (HCPT), 2ml:2mg, Huangshi Feiyun Pharmaceutical Co., Ltd., lot number: 041001.
1.2 subject cell strain
Select the human lung cancer cell A549 for use, the low differentiation of people adenocarcinoma of stomach cell BGC-823, human liver cancer cell SMMC-7721, four cell strains of human promyelocytic leukemia cell HL-60.
1.3 test method
Get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestive juice, digestion comes off attached cell, counting 2～4 * 10
4Individual/ml, make cell suspension.Obtained cell suspension is inoculated on 96 orifice plates, and constant temperature CO is put in 180 μ l/ holes
2Cultivated 24 hours in the incubator.Change liquid, adding is subjected to the reagent thing, and cultivated 48 hours in 20 μ l/ holes.MTT is added in 96 orifice plates, 20 μ l/ holes, reaction is 4 hours in the incubator.Supernatant liquor is removed in suction, adds DMSO, 150 μ l/ holes, and jolting is 5 minutes on the dull and stereotyped shaking table.Tried thing and investigated three concentration (1 * 10
-7, 1 * 10
-6, 1 * 10
-5Mol/L), be the light absorption value that the 570nm place measures every hole with enzyme-linked immunosorbent assay instrument at wavelength, calculate the cell inhibitory rate under each concentration respectively.
Cell inhibitory rate %=(negative control group OD value-susceptibility group OD value)/negative control group OD value * 100%
1.4 antitumor activity screening judging criterion
In the extracorporeal anti-tumor function screening, the dissimilar positive effect judging criterions of being tried thing see the following form:
| Known molecular quantizes compound mol/L | Unknown compound μ g/ml | Crude extract μ g/ml | Cell inhibitory rate % | Active |
| 1×10 -7 1×10 -6 1×10 -5 | 1 10 100 | 2 20 200 | ≥50 ≥50 ≥50 | +++potent |
| 1×10 -7 1×10 -6 1×10 -5 | 1 10 100 | 2 20 200 | ＜50 ≥50 ≥50 | ++ |
| 1×10 -7 1×10 -6 1×10 -5 | 1 10 100 | 2 20 200 | ＜50 ＜50 ≥50 | + weak effect |
1.5 The selection result
XY-8 sees Table 1 to the antitumor action The selection result of vitro culture human tumor cells.Wherein XY-8 has weak effect to the low differentiation of people adenocarcinoma of stomach cell BGC-823; Have potent to human promyelocytic leukemia cell HL-60 and human lung cancer cell A549.
Table 1. XY-8 is to the antitumor action The selection result of vitro culture human tumor cells
| Cell strain | Tried thing | Final concentration mol/L | Cell inhibitory rate % | Active |
| A549 | XY-8 | 1×10 -7 1×10 -6 1×10 -5 | 53.88 a 87.35 99.59 | +++ |
| Mitomycin | 1×10 -7 1×10 -6 1×10 -5 | 18.42 41.93 89.46 | + | |
| BGC-823 | XY-8 | 1×10 -7 1×10 -6 1×10 -5 | 31.28 44.70 50.66 | + |
| Cis- | 1×10 -7 1×10 -6 1×10 -5 | 11.00 10.90 92.94 | + | |
| HL-60 | XY-8 | 1×10 -7 1×10 -6 1×10 -5 | 70.41 91.82 97.32 | +++ |
| Cis- | 1×10 -7 | 24.82 | + |
| 1×10 -6 1×10 -5 | 46.37 96.79 | |||
| SMMC-7721 | XY-8 | 1×10 -7 1×10 -6 1×10 -5 | 27.63 17.40 33.45 | - |
| | 1×10 -7 1×10 -6 1×10 -5 | 5.03 49.14 61.68 | + |
a: the antitumor drug primary-screened sample is counted n=3
2. XY-8 is to the inhibiting IC of vitro culture human lung cancer cell A549
50Value
2.1 tried thing
XY-8 Hefei ZhongKeDa Bioisystech Co., Ltd provides.Positive drug alkyl camptothecine injection (HCPT), 2ml:2mg, Huangshi Feiyun Pharmaceutical Co., Ltd., lot number: 041001.
2.2 subject cell strain
Select the human lung cancer cell A549 for use.
2.3 test method
Get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestive juice, digestion comes off attached cell, counting 2～4 * 10
4Individual/ml, make cell suspension.Obtained cell suspension is inoculated on 96 orifice plates, and constant temperature CO is put in 180 μ l/ holes
2Cultivated 24 hours in the incubator.Change liquid, adding is subjected to the reagent thing, and cultivated 48 hours in 20 μ l/ holes.MTT is added in 96 orifice plates, 20 μ l/ holes, reaction is 4 hours in the incubator.Supernatant liquor is removed in suction, adds DMSO, 150 μ l/ holes, and jolting is 5 minutes on the dull and stereotyped shaking table.Tried thing and investigated 6 concentration (1 * 10
-8～1 * 10
-5Mol/L), be the light absorption value that the 570nm place measures every hole with enzyme-linked immunosorbent assay instrument at wavelength, calculate cell inhibitory rate under each concentration respectively, use IC
50Software for calculation calculates test-compound IC
50
Cell inhibitory rate %=(negative control group OD value-susceptibility group OD value)/negative control group OD value * 100%
2.4 result
| Tried thing | Final concentration mol/L | IC 50 μmol/L | Tried thing | Final concentration mol/L | IC 50 μmol/L |
| HCPT | 1×10 -7 3×10 -7 1×10 -6 3×10 -6 1×10 -5 | 13.8±8.6 | XY-8 | 1×10 -8 3×10 -8 1×10 -7 3×10 -7 1×10 -6 1×10 -5 | 8.1±3.2 |
| 3×10 -5 |
Annotate: each sample IC50 repetition measurement frequency n 〉=3.
Two, XY-8 is to the experimental therapy effect of mice transplanted tumor
1. materials and methods
1.1 animal
50 of ICR mouse, female, 18-22g is provided by animal housing of China Medicine University, conformity certification number: kinoplaszm SCXK (Soviet Union) 2002--0011 of Soviet Union.
1.2 knurl kind
Mouse S180 sarcoma and H22 liver cancer are provided by institute of materia medica, Chinese Academy of Sciences Shanghai.
1.3 tried thing
XY-8 Hefei ZhongKeDa Bioisystech Co., Ltd provides.Positive drug alkyl camptothecine injection (HCPT), 2ml:2mg, Huangshi Feiyun Pharmaceutical Co., Ltd., lot number: 041001.
2. test method
2.1 XY-8 is to the experimental therapy effect of mouse S180 sarcoma
Select well-grown 7～11 days S180 knurl kind for use, it is subcutaneous to be inoculated in the right side of mice armpit, and about 4.5～5 * 10
6Cell/only, inoculate and divide cage at random after 24 hours, intravenously administrable, administration volume are 0.4ml/.Tried thing XY-8 and established 10,5, three dosage groups of 2.5mg/kg, positive drug HCPT establishes 8mg/kg, each is organized in inoculation back administration in the 2nd, 5 day.Measure body weight every day during the administration, put to death animal on the 8th day, claims knurl heavy, and it is heavy that average knurl is respectively organized in calculating, presses formula and obtain tumor control rate and carry out the t check.
2.2 XY-8 is to the experimental therapy effect of mouse H22 liver cancer
Test method is with S180 sarcoma test, tried thing XY-8 and establishes 10,5, three dosage groups of 2.5mg/kg, and positive drug HCPT establishes 8mg/kg.
3. result
3.1 XY-8 is to the experimental therapy effect of mouse S180 sarcoma
The results are shown in Table 4.Compare with the physiological saline control group, three dosage groups of XY-8 10,5,2.5mg/kg all can significantly suppress tumor growth (P＜0.01), and wherein the effect of XY-8 10mg/kg obviously is better than HCPT8mg/kg (P＜0.01).
Table 4. XY-8 is to the tumor growth restraining effect of mouse S180 sarcoma (x ± sd)
| Group | Dosage mg/kg | Number of animals | Body weight (g) | Knurl heavy (g) | Inhibition rate of tumor growth (%) | ||
| d1 | d7 | d1 | d7 | ||||
| Physiological saline HCPT XY-8 XY-8 XY-8 | 8 10 5 2.5 | 10 10 10 10 10 | 10 10 10 10 10 | 24.4±1.0 24.3±1.7 24.5±1.1 25.2±1.0 23.8±1.1 | 29.1±0.7 28.4±1.9 28.0±1.3 28.4±0.9 28.5±0.7 | 1.09±0.52 0.31±0.21 ** 0.10±0.08 **，## 0.18±0.12 ** 0.32±0.10 ** | 71.3 90.7 83.4 70.4 |
D1, d7: inoculation back the 1st, 7 day;
*Compare with the physiological saline group P＜0.01;
##Compare with the HCPT group P＜0.01.
3.2 XY-8 is to the experimental therapy effect of mouse H22 liver cancer
The results are shown in Table 5.Compare with the physiological saline control group, three dosage groups of XY-8 10,5,2.5mg/kg all can significantly suppress tumor growth (P＜0.01), and wherein the effect of XY-8 10,5mg/kg obviously is better than HCPT8mg/kg (P＜0.01, P＜0.05).
Table 5. XY-8 is to the tumor growth restraining effect of mouse H22 liver cancer (x ± sd)
| Group | Dosage mg/kg | Number of animals | Body weight (g) | Knurl heavy (g) | Inhibition rate of tumor growth (%) | ||
| d1 | d7 | d1 | d7 | ||||
| Physiological saline HCPT XY-8 XY-8 XY-8 | 8 10 5 2.5 | 10 10 10 10 10 | 10 10 10 10 10 | 20.2±0.8 20.1±0.7 19.7±0.8 20.1±0.8 19.6±0.9 | 27.0±2.8 25.2±1.5 21.0±1.9 23.2±1.3 24.4±1.5 | 1.12±0.45 ** 0.77±0.63 ** 0.18±0.11 **，## 0.24±0.17 **，# 0.42±0.23 ** | 30.7 83.8 78.6 62.3 |
D1, d7: inoculate the 1st, 7 day;
*Compare with the physiological saline group P＜0.01;
#P＜0.05,
##Compare with the HCPT group P＜0.01.
Three, XY-8 is to the experimental therapy effect of people's cancer Nude Mice
1. purpose
Investigate new compound XY-8 people's cancer Nude Mice is had or not growth-inhibiting effect and action intensity
2. materials and methods
2.1 tried thing
New compound XY-8 is provided by Hefei ZhongKeDa Bioisystech Co., Ltd, is pale yellow powder, and is soluble in water, prepares desired concn with physiological saline before the administration; Positive drug alkyl camptothecine injection (HCPT), 2ml:2mg, Huangshi Feiyun Pharmaceutical Co., Ltd., lot number: 041001, be diluted to desired concn with physiological saline before each administration.
2.2 transplanted tumor
Select human lung adenocarcinoma A-549 Nude Mice, people's adenocarcinoma of stomach BGC-823 Nude Mice, people's adenocarcinoma of stomach SGC-7901 Nude Mice for use, it is subcutaneous and set up to be inoculated in nude mouse by human lung adenocarcinoma A-549, people's adenocarcinoma of stomach BGC-823 and people's adenocarcinoma of stomach SGC-7901 cell strain respectively.The cell inoculation amount is 2 * 10
6, inoculation is used after forming and passing for 3 generations again in the nude mouse body behind the transplanted tumor.
2.3 animal
Female BALB/cA nude mouse, age in days 35-40 days, body weight 18-22g was provided by Chinese Academy of Sciences's Shanghai Experimental Animal Center.The conformity certification numbering: Shanghai is moving closes the card word No. 122.10 of the negative control groups of every treated animal number, 5 of administration groups.
2.4 test method
The tumor tissue of getting the growth animated period cuts into 1.5mm
3About, under aseptic condition, it is subcutaneous to be inoculated in nude mouse right side armpit.Nude Mice is treated tumor growth to 100～300mm with vernier caliper measurement transplanted tumor diameter
3After with the animal random packet.Use the method for measuring the knurl footpath, dynamic observe the antineoplastic effect of tested thing.The measurement number of times of diameter of tumor is that each the measurement also need claim mouse heavy simultaneously 3 times weekly.The administration group is intravenously administrable 3 times weekly, and positive controls is intravenously administrable 2 times weekly, and negative control group is given equivalent physiological saline simultaneously.
2.5 detect index and method of calculation
(1) gross tumor volume (tumor volume, TV), calculation formula is:
TV＝1/2×a×b
2
Wherein a, b represent length and width respectively.
(2) relative tumour volume (relative tumor volume, RTV), calculation formula is:
RTV＝TV
t/TV
0。
TV wherein
0(d during for minute cage administration
0) gross tumor volume, TV
tGross tumor volume when measuring each time.
(3) relative tumor proliferation rate T/C (%), calculation formula is:
T
RTV: treatment group RTV; C
RTV: negative control group RTV.
Test-results is with the evaluation index of relative tumor proliferation rate T/C (%) as anti-tumor activity.
3. result
3.1 XY-8 is to the experimental therapy effect of human lung adenocarcinoma A-549 Nude Mice
XY-8 sees Table 6 and Fig. 1 to the experimental treatment result of human lung adenocarcinoma A-549.XY-8 has certain growth-inhibiting effect to human lung adenocarcinoma A-549 Nude Mice.It is 60.7,103.6 and 53.6 that XY-8 2.5,5 and 10mg/kg dosage group are respectively the T/C (%) of A-549, and HCPT 8mg/kg dosage group T/C (%) is 71.4.Experimental group does not have obvious toxicity.
Table 6.XY-8 is to the experimental therapy effect of human lung adenocarcinoma A-549 Nude Mice
| Group | Dosage mg/kg | Number of animals | Body weight (g) | TV | RTV | T/C (％) | |||
| Beginning | At last | Beginning | At last | d0 | d17 | ||||
| NS HCPT XY-8 XY-8 XY-8 | 8 10 5 2.5 | 10 5 5 5 5 | 10 5 5 5 5 | 21.4±1.4 21.3±1.7 20.7±0.6 21.5±0.9 21.3±0.5 | 22.5±1.3 22.4±1.8 23.4±2.5 22.1±1.1 22.7±1.0 | 128±71 131±54 132±134 126±72 120±23 | 390±342 258±137 211±237 407±365 200±73 | 2.8±1.0 2.0±0.5 1.5±0.4 * 2.9±1.3 1.7±0.5 * | 71.4 53.6 103.6 60.7 |
D0: divide the cage administration time
3.2 XY-8 is to the experimental therapy effect of people's adenocarcinoma of stomach BGC-823 Nude Mice
XY-8 sees Table 7 and Fig. 2 to the experimental treatment result of people's adenocarcinoma of stomach BGC-823.XY-8 has certain growth-inhibiting effect to people's adenocarcinoma of stomach BGC-823 Nude Mice.XY-8 2.5,5 and 10mg/kg dosage group are respectively 39.8,36.6 and 27.3 to the T/C (%) of A-549, and HCPT 8mg/kg dosage group T/C (%) is 37.3.Experimental group does not have obvious toxicity.
Table 7. XY-8 is to the experimental therapy effect of people's adenocarcinoma of stomach BGC-823 Nude Mice
| Group | Dosage mg/kg | Number of animals | Body weight (g) | TV | RTV | T/C (％) | |||
| Beginning | At last | Beginning | At last | d0 | d17 | ||||
| NS HCPT XY-8 XY-8 XY-8 | 8 10 5 2.5 | 10 5 5 5 5 | 10 5 5 5 5 | 20.4±1.3 20.5±3.6 20.0±0.8 20.6±0.8 21.0±1.0 | 22.9±1.3 21.8±3.2 21.0±1.1 21.6±1.1 22.6±1.3 | 190±83 185±90 184±20 187±67 181±61 | 2793±1117 1119±327 774±132 1054±415 1108±368 | 16.1±5.9** 6.0±1.1** 4.4±1.0** 5.9±2.2** 6.4±2.3** | 37.3 27.3 36.6 39.8 |
D0: divide the cage administration time
3.3 XY-8 is to the experimental therapy effect of people's adenocarcinoma of stomach SGC-7901 Nude Mice
XY-8 sees Table 8 and Fig. 3 to the experimental treatment result of people's adenocarcinoma of stomach SGC-7901.XY-8 has certain growth-inhibiting effect to people's adenocarcinoma of stomach SGC-7901 Nude Mice.XY-8 2.5,5 and 10mg/kg dosage group are respectively 82.2,62.5 and 43.3 to the T/C (%) of A-549, and HCPT 8mg/kg dosage group T/C (%) is 54.8.Experimental group does not have obvious toxicity.
Table 8. XY-8 is to the experimental therapy effect of people's adenocarcinoma of stomach SGC-7901 Nude Mice
| Group | Dosage mg/kg | Number of animals | Body weight (g) | TV | RTV | T/C (％) | |||
| Beginning | At last | Beginning | At last | d0 | d17 | ||||
| NS HCPT XY-8 XY-8 XY-8 | 8 10 5 2.5 | 10 5 5 5 5 | 10 5 5 5 5 | 19.7±1.1 19.5±0.7 19.7±1.2 19.7±0.7 20.0±0.6 | 23.5±1.6 22.2±1.3 20.5±1.7 20.2±2.8 23.4±1.1 | 263±98 283±140 272±56 273±146 251±42 | 5671±1701 3009±1419 2382±589 3241±1203 4510±727 | 20.8±5.7 11.4±2.9** 9.0±2.3** 13.0±3.8** 17.1±1.6 | 54.8 43.3 62.5 82.2 |
D0: divide the cage administration time
The anti-tumor activity experiment of other new camptothecin derivatives
1 experimental result
| Sample number into spectrum | Final concentration (mol/L) | The low differentiation of people adenocarcinoma of stomach cell BGC-823 | Human promyelocytic leukemia cell HL-60 | The human lung cancer cell A549 | Human liver cancer cell SMMC-7721 |
| Inhibiting rate (%) | Inhibiting rate (%) | Inhibiting rate (%) | Inhibiting rate (%) | ||
| XY-8 | 1×10 -7 1×10 -6 1×10 -5 | 31.28 44.70 50.66 | 70.41 91.82 97.32 | 53.88 87.35 99.59 | 27.63 17.40 33.45 |
| | 1×10 -7 1×10 -6 1×10 -5 | 19.78 25.53 24.72 | 1.41 49.88 89.68 | 12.24 31.63 87.35 | 19.03 19.74 17.26 |
| | 1×10 -7 1×10 -6 1×10 -5 | 12.51 29.16 53.48 | 28.91 80.54 95.86 | 41.84 85.71 95.71 | 23.07 22.94 55.33 |
| | 1×10 -7 1×10 -6 1×10 -5 | 33.20 35.72 63.57 | 55.72 85.50 94.01 | 17.14 85.51 96.94 | 29.62 33.88 53.91 |
| | 1×10 -7 1×10 -6 1×10 -5 | 26.94 19.27 26.84 | 5.35 26.28 74.21 | 5.71 12.24 63.27 | 13.14 14.70 17.26 |
| | 1×10 -7 1×10 -6 1×10 -5 | 19.78 11.81 17.76 | 0.00 58.35 91.48 | 6.37 28.37 90.20 | 14.91 21.38 4.05 |
Wherein XY-8 represents 21-N[3-(1-morpholinyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=H, the Y=1-morpholinyl), Bam represents 21-N[3-(1-morpholinyl) propyl group] and acid amides-17-acetoxyl group E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
3, the Y=1-morpholinyl), Ban represents 21-N[3-(1-morpholinyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
2CH
3, the Y=1-morpholinyl), Ab represents 21-N[3-(1-imidazolyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=H, the Y=1-imidazolyl), Bbm represents 21-N[3-(1-imidazolyl) propyl group] and acid amides-17-acetoxyl group E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
3, the Y=1-imidazolyl), Bbn represents 21-N[3-(1-imidazolyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine (R
1=H, R
2=-CH
2CH
2CH
2-, R
3=R
4CO, R
4=-CH
2CH
3, the Y=1-imidazolyl).
2 experimental techniques: mtt assay
1. get and be in one bottle in cell in good condition exponential phase of growth, add 0.25% tryptic digestive juice, digestion comes off attached cell, counting 2～4 * 10
-4Individual/mL, make cell suspension.
2. obtained cell suspension is inoculated on 96 orifice plates, and constant temperature CO is put in 180 μ l/ holes
2Cultivated 24 hours in the incubator.
3. change liquid, adding is subjected to the reagent thing, and cultivated 48 hours in 20 μ l/ holes.
4. MTT is added in 96 orifice plates, 20 μ l/ holes, reaction is 4 hours in the incubator.
5. inhale and go supernatant, add DMSO, 150 μ l/ holes, jolting is 5 minutes on the dull and stereotyped shaking table.
6. be the light absorption value that the 570nm place measures every hole with enzyme-linked immunosorbent assay instrument at wavelength, and calculate cell and suppress.
The XY-8 intravenously administrable is to the acute toxicity test of mouse
The The acute toxicity tests of XY-8 shows: mouse mainline is the LD of administration (iv)
50Value is 269.7mg/kg.The toxicity symptom of mouse shows as the minimizing of ingesting, and spontaneous activity obviously descends, and abdomen crouches, blepharoptosis, and irritant reaction is blunt to external world, and animal is quiet and die.Animal dead promptly occurs behind the maximum dose level group administration 3h, each dosage treated animal death all occurs in the 48h, and after about 48 hours, the mouse activity begins to increase and recovers normal.Dead mouse gross necropsy, internal organs are not seen obvious pathology.
Test-results is pressed the Bliss method and is calculated, and records the LD of mouse iv XY-8
50Value is 269.7mg/kg, and its fiducial limit of 95% is 257.7～280.2mg/kg.
Description of drawings:
Fig. 1 .XY-8 is to the effect of people's lung cancer A-549 Nude Mice growth-inhibiting
Fig. 2 .XY-8 is to the effect of people's adenocarcinoma of stomach BGC-823 Nude Mice growth-inhibiting
Fig. 3 .XY-8 is to the effect of people's adenocarcinoma of stomach SGC-7901 Nude Mice growth-inhibiting
Embodiment:
Further specify the present invention by the following examples:
Embodiment one: N-(3-aminopropyl) morpholine is separated open loop product (1) XY-8 to the ammonia of CPT preparation
105mg (0.3mmol) CPT is dissolved in 15ml methyl alcohol, adds 1.2 normal ammonia and separates reagent N-(3-aminopropyl) morpholine (3) a, after reacting 14 hours under 75 ℃, system becomes clarification, and reaction mixture is poured in the ether, separates out yellow mercury oxide, leach precipitation, wash with cold diethyl ether.Can find out by TLC, contain unreacted CPT in the product.Product is dissolved in a small amount of CHCl
3, separate (eluent: ethyl acetate: sherwood oil=1: 1 → 4: 1) get pure open-loop products (1) XY-8 106mg, productive rate 88% with alumina column chromatography.
IR(KBr)ν：1620.61cm
-1(-
CONH-)。
1HNMR(CDCl
3，300MHz)δppm：1.07(t，J＝7.20Hz，3H，18-CH
3)，1.76(m，2H，19-CH
2)，2.25(m，1H，22-CH
2)，2.43(m，1H，22-CH
2)，2.44(m，6H，22-CH
2，and 2 x24-CH
2)，3.41(m，2H，21-CH
2)，3.75(m，4H，2 x 25-CH
2)，4.88(q，J
AB＝12.70Hz，2H，17-CH
2)，5.04(s，2H，5-CH
2)，7.47(t，J＝8.4Hz，1H，10-H)，7.48(s，1H，14-H)，7.56(d，J＝7.20Hz，1H，9-H)，7.67(t，J＝5.20Hz，2H，11-H)，7.87(s，1H，7-H)，7.97(d，J＝8.46Hz，1H，12-H)，8.20(s，1H，NH)。
The ammonia of embodiment two, CPT is separated the preparation of 17-glycoloyl product (1) Bam of open loop product (1) XY-8
CPT open-loop products (1) XY-8 (0.25mmol) of 126mg N-(3-aminopropyl) morpholine is dissolved in 2mL (24.8mmol) pyridine, adds 1mL (10.6mmol) diacetyl oxide, and heating makes temperature maintenance about 40 ℃, and stirring is spent the night.The pressure reducing and steaming solvent.The a spot of CHCl of residue
3Dissolving is poured in the mixed solution of 20mL sherwood oil ether equal-volume ratio, separates out precipitation, filters the cold diethyl ether washing.Use CHCl again
3Dissolving, purification by silica gel column chromatography (eluent: ethyl acetate: sherwood oil=2: 1 → pure ethyl acetate), get xanchromatic pressed powder (1) Bam 112mg.Productive rate 81.9%.
IR(KBr)ν：1733.69cm
-1(-
CO-CH
3)，1620.61cm
-1(-
CONH-)。
1HNMR(CDCl
3，300MHz)δppm：1.10(t，J＝7.17Hz，3H，18-CH
3)，1.77(m，2H，19-CH
2)，2.06(s，3H，-CO-C
H 3)，2.30(m，1H，22-CH
2)，2.52～2.54(m，7H，23-CH
2，2 x24-CH
2，1/2 x 22-CH
2)，3.31～3.42(m，2H，21-CH
2)，3.78(d，J＝4.38Hz，4H，25-CH
2)，5.15(q，J＝19.41Hz，2H，5-CH
2)，5.47(dd，J
AB＝11.58Hz，2H，17-CH
2)，7.43(t，J＝7.42Hz，1H，10-H)，7.58(s，1H，14-H)，7.63(d，J＝8.11Hz，1H，9-H)，7.69(t，J＝7.23Hz，1H，11-H)，8.04(d，J＝8.34Hz，1H，12-H)，8.14(s，1H，7-H)，8.17(s，1H，N
H)
The ammonia of embodiment three, CPT is separated the preparation of 17-hydroxyl propionyl product (1) Ban of open loop product (1) XY-8
CPT open-loop products (1) XY-8 of 150mg (0.30mmol) N-(3-aminopropyl) morpholine, 1.5mL pyridine (18.6mmol) and 1mL propionic anhydride (7.7mmol) are mixed and heated to 40 ℃, stirring is spent the night, boil off low boiling point solvent, residuum is poured the 50mL ether into, separate out faint yellow solid, be further purified (eluent: ethyl acetate: sherwood oil=1: 1 → 3: 1) get (1) Bam straight product 111mg, productive rate 66.4% through silica gel column chromatography.
IR(KBr)ν：1729.83cm
-1(-
COCH
2CH
3)，1654.52cm
-1(-
CONH-)
1HNMR.(CDCl
3，300MHz)δppm：1.11(t，J＝7.23Hz，3H，18-CH
3)，1.21(t，J＝7.05Hz，3H，-CO-C-
CH 3)，1.77(m，2H，19-CH
2)，2.31(m，1H，1/2 x 22-CH
2)，2.40～2.15(m，1H，1/2 x 22-CH
2)，2.55～2.56(m，6H，23-CH
2 and 2 x 24-CH
2)，3.32(m，1H，1/2 x 21-CH
2)，3.44(m，1H，1/2 x 21-CH
2)，3.48(q，J＝6.99Hz，2H，-CO-CH
2-)，3.79(t，J＝4.50Hz，4H，2 x 25-CH
2)，5.13(q，J＝19.17Hz，2H，5-CH
2)，5.47(q，J
AB＝11.58Hz，2H，17-CH
2)，7.45(t，J＝7.41，1H，10-H)，7.57(s，1H，14-H)，7.60(d，J＝8.10，1H，9-H)，7.68(t，J＝7.51，1H，11-H)，8.03(d，J＝8.46，1H，12-H)，8.12(s，1H，7-H)，8.21(s，1H，NH)。
Embodiment four, 1-(3-aminopropyl) imidazoles is separated open loop product (1) Ab to the ammonia of CPT preparation:
639mg CPT (1.84mmol) and about 1.2 normal 1-(3-aminopropyl) imidazoles and 1mL CHCl
3, to stir, heating (about 60 ℃) to becoming clarification, boils off CHCl
3, debris is poured the NHCl of 40mL into
4Saturated solution is with the CHCl of 5 * 40mL
3Extraction merges organic phase, and anhydrous sodium sulfate drying concentrates, silica gel column chromatography purification (eluent: ethyl acetate: sherwood oil=2: 1 → pure ethyl acetate), finally obtain yellow powder shape solid (1) Ab 815mg.Productive rate 93.7%.
IR(KBr)ν：1651.08cm
-1(-
CONH-)
1HNMR.(CDCl
3，300MHz)δppm：1.06(t，J＝6.44Hz，3H，18-CH
3)，2.05(m，2H，19-CH
2)，2.30～2.39(m，2H，22-CH
2)，3.33(m，2H，21-CH
2)，4.01(t，J＝6.97Hz，2H，23-CH
2)，4.92(dd，J
AB＝12.64Hz，2H，17-CH
2)，5.04(s，2H，5-CH
2)，6.94(s，1H，)，7.01(s，1H，)，7.45(t，J＝7.23Hz，1H，10-H)，7.51(d，J＝7.10Hz，1H，9-H)，7.56(s，1H，14-H)，7.65(d，J＝9.11Hz，1H，12-H)，7.70(t，J＝7.42Hz，1H，11-H)，8.03(s，1H，)，8.05(s，1H，7-H)。
The ammonia of embodiment five, CPT is separated the preparation of 17-glycoloyl product (1) Bbm of open loop product (1) Ab
153mg (0.32mmol) (1) Ab is dissolved in the pyridine of 1.8mL (22.3mmol), adds the diacetyl oxide of 1.2mL (12.7mmol).Heating makes temperature about 50 ℃, spends the night.Cooling, rotation boils off partial solvent, uses ether sedimentation then, filters.Solid is at (the eluent: ethyl acetate: sherwood oil=2: 1 → pure ethyl acetate), finally obtain dry yellow solid powdered product (1) Bbm 123mg of purifying by silica gel column chromatography.Productive rate: 88.4%.
IR(KBr)ν：1722.12cm
-1(-
CO-CH
3)，1651.08cm
-1(-
CONH-)
1HNMR.(CDCl
3，300MHz)δppm：1.07(t，J＝7.20Hz，3H，18-CH
3)，2.06(s，3H，-CO-C
H 3)，2.10(m，2H，19-CH
2)，2.32～2.46(m，2H，22-CH
2)，3.33(m，2H，21-CH
2)，4.07(t，J＝7.02Hz，2H，23-CH
2)，5.20(m，2H，5-CH
2)5.52(dd，J
AB＝11.49Hz，2H，17-CH
2)，7.01(s，1H，)，7.10(s，1H，)，7.54(t，J＝7.23Hz，1H，10-H)，7.61(s，1H，14-H)，7.76(d，1H，J＝7.13，9-H)，7.79(t，J＝7.42Hz，1H，11-H)，7.82(s，1H，)，8.12(d，J＝9.11Hz，1H，12-H)，8.23(s，1H，7-H)。
The ammonia of embodiment six, CPT is separated the preparation of 17-hydroxyl propionyl product (1) Bbn of open loop product (1) Ab
127mg (0.27mmol) (1) Ab is dissolved in 1.5mL (18.6mmol) pyridine, adds 1.0mL (7.7mmol) propionic anhydride.Be heated to about 50 ℃, stirring is spent the night.The pressure reducing and steaming partial solvent is used sherwood oil-ether sedimentation then, filters.Solid is through purification by silica gel column chromatography (eluent: ethyl acetate: sherwood oil=2: 1 → pure ethyl acetate), get yellow solid powder (1) Bbn 103mg.Productive rate: 72.4%.
IR(KBr)ν：1726.12cm
-1(-
CO-C
2H
5)，1652.23cm
-1(-
CONH-)
1HNMR.(CDCl
3，300MHz)δppm：1.01(t，J＝7.13Hz，3H，18-CH
3)，1.23(t，J＝7.11，3H，-CO-C-C
H 3)，2.04(m，2H，19-CH
2)，2.30～2.47(m，4H，-CO-C
H 2-and 22-CH
2)，3.31(m，2H，21-CH
2)，4.04(t，J＝6.99Hz，2H，23-CH
2)，5.16(m，2H，5-CH
2)5.52(dd，J
AB＝11.61Hz，2H，17-CH
2)，6.98(s，1H，)，7.06(s，1H，)，7.51(t，J＝7.18Hz，1H，10-H)，7.59(s，1H，14-H)，7.60(s，1H，)，7.67(d，1H，J＝7.07，9-H)，7.73(t，J＝7.42Hz，1H，11-H)，8.01(d，J＝9.02Hz，1H，12-H)，8.18(s，1H，7-H)。
Claims (6)
- A structure as shown in the formula camptothecin derivative
Wherein:R 1Represent 9,10 or the 11-position on 0-3 identical or different substituting group, these substituting groups are selected from halogen atom, hydroxyl or alkoxyl group;R 2Represent C 2-C 5The straight or branched alkylidene group;R 3Represent hydrogen atom or R 4CO-, R 4Represent low alkyl group, lower alkyl amino alkylidene group or lower alkoxy alkylidene group; Be selected from-CH 3,-(CH 2) nCH 3,-(CH 2) nOCH 3,-(CH 2) nNHCH 3,-(CH 2) nN (CH 3) 2, n=1-3 wherein;Y represents alkaline heterocyclic radical or hydrogenant alkalescence heterocyclic radical, is selected from imidazoles, pyridine, pyrimidine, pyrazine, piperidines, piperazine, morpholine. - 2. the camptothecin derivative of claim 1,Wherein:R 1Represent H, OHR 2Representative-CH 2CH 2CH 2-R 3Represent H, R 4COR 4Representative-CH 3,-CH 2CH 3Y represents 1-imidazolyl, 1-morpholinyl.
- 3. the camptothecin derivative of claim 1 is following compound:21-N[3-(1-morpholinyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine,21-N[3-(1-morpholinyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine,21-N[3-(1-morpholinyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine.
- 4. the preparation method of the camptothecin derivative of claim 1 is characterized in that, prepares through following steps:Camptothecine or derivatives thereof raw material and excessive N H with general formula (2) representative 2-(CH 2) n-Y compound reaction generates corresponding opened loop compound to open lactonic ring, as required, further with the compound after the open loop with corresponding acylating agent with 17-hydroxyl acylations,
R in the formula 1Define with claim 1 n=2-5 with Y. - 5. the preparation method of claim 4 is characterized in that, wherein acylating agent is selected from: Acetyl Chloride 98Min., propionyl chloride, diacetyl oxide, propionic anhydride.
- 6. the preparation method of claim 4 is characterized in that, the further acylations product of 17-hydroxyl is after open-loop products and the open loop:21-N[3-(1-morpholinyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine,21-N[3-(1-morpholinyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine,21-N[3-(1-morpholinyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-hydroxyl E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-acetoxyl group E lactonic ring open loop camptothecine,21-N[3-(1-imidazolyl) propyl group] acid amides-17-propionyloxy E lactonic ring open loop camptothecine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100987438A CN100339377C (en) | 2005-09-05 | 2005-09-05 | Camptothecine derivative and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100987438A CN100339377C (en) | 2005-09-05 | 2005-09-05 | Camptothecine derivative and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1821245A CN1821245A (en) | 2006-08-23 |
| CN100339377C true CN100339377C (en) | 2007-09-26 |
Family
ID=36922838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100987438A Expired - Fee Related CN100339377C (en) | 2005-09-05 | 2005-09-05 | Camptothecine derivative and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100339377C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1319971C (en) * | 2005-09-09 | 2007-06-06 | 合肥中科大生物技术有限公司 | Camptothecine derivatives and their use |
| CN110003142A (en) * | 2018-01-04 | 2019-07-12 | 深圳福山生物科技有限公司 | A kind of synthesis and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126212A (en) * | 1994-09-06 | 1996-07-10 | 株式会社雅库路特本社 | Camptothecin derivatives, preparations thereof and antitumor agents |
| CN1192740A (en) * | 1995-06-21 | 1998-09-09 | 科学研究与运用咨询公司 | Novel camptothecin analogues, prepn. method therefor, use thereof, and pharmaceutical compositions contg. same |
| US6121277A (en) * | 1996-05-10 | 2000-09-19 | Indena S.P.A. | Camptothecin-skeleton compounds isolated from Mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents |
| CN1821247A (en) * | 2005-09-09 | 2006-08-23 | 合肥中科大生物技术有限公司 | Camptothecine derivatives and their use |
-
2005
- 2005-09-05 CN CNB2005100987438A patent/CN100339377C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126212A (en) * | 1994-09-06 | 1996-07-10 | 株式会社雅库路特本社 | Camptothecin derivatives, preparations thereof and antitumor agents |
| CN1192740A (en) * | 1995-06-21 | 1998-09-09 | 科学研究与运用咨询公司 | Novel camptothecin analogues, prepn. method therefor, use thereof, and pharmaceutical compositions contg. same |
| US6121277A (en) * | 1996-05-10 | 2000-09-19 | Indena S.P.A. | Camptothecin-skeleton compounds isolated from Mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents |
| CN1821247A (en) * | 2005-09-09 | 2006-08-23 | 合肥中科大生物技术有限公司 | Camptothecine derivatives and their use |
Non-Patent Citations (1)
| Title |
|---|
| DNA拓扑异构酶I抑制药 王磊等,China Pharmacist,Vol.6 No.7 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1821245A (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1094720A (en) | New taxoids, its preparation and the pharmaceutical composition that contains them | |
| WO1993002065A1 (en) | New derivatives of taxol analogues, preparation thereof and compositions containing them | |
| CN1680358A (en) | Composition concerned with isoflavone and the similar and therapeutical method | |
| CN1046934C (en) | Acylfulvene analogues as antitumor agents | |
| CN1708495A (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
| CN1121380C (en) | Anti-tumor bis-dicarboxylic diamino platinum derivatives and its medicinal composition | |
| CN113801073B (en) | 14-chloro-beta-elemene nitric oxide donor type derivative and preparation and application thereof | |
| CN1039910C (en) | Calanthamine derivatives, a process for their preparation and their use as medicaments | |
| CN1250546C (en) | Tetrahydropyrido compound | |
| CN1027371C (en) | Synthetic process of diterpenic lactone | |
| CN1047866A (en) | The preparation method of N-heteroaryl-purine-6-amine and medicinal | |
| CN1807404A (en) | Resveratrol derivative and its production method and uses | |
| CN1126723A (en) | Preparation of derivative of 4-deoxcide-4-surface-podocyllin poison | |
| CN100339377C (en) | Camptothecine derivative and its preparation | |
| CN1319971C (en) | Camptothecine derivatives and their use | |
| CN1474703A (en) | Taxoid conjugates as antimitotic and antitumor agents | |
| CN1009826B (en) | The method for preparing quinoline compound | |
| CN1902671A (en) | Language phonetic system | |
| CN1649873A (en) | Camptothecin-taxoid conjugates as antimitotic and antitumor agents | |
| CN1046726C (en) | Imidazopyridine-pyrrolidone and imidazopyridine-oxaolidone | |
| CN1280279C (en) | Dibenzo-isozaolone compounds and their synthesis process and application | |
| CN101029034A (en) | Polyenic taxol soluble derivative, its preparation and use | |
| CN1931869A (en) | Derivative of 5-deoxy-5-fluoro cytidine and its prepn process and use | |
| CN1282332A (en) | Novel acronycine compounds, preparation method and pharmaceutical compositions containing them | |
| CN1511835A (en) | Benzo-isoselenazole derivatives having anti inflammation, anti-tumor and anti-thrumbosis function and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HEFEI USTC BIOTECHNOLOGY CO., LTD. Free format text: FORMER NAME: HEFEI ZHONGKEDA BIO-TECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 230088, Anhui province high tech Zone, 425 innovation Avenue, Anhui province science and technology achievement demonstration base D, Hefei Patentee after: Hefei Keda Biological Technology Co., Ltd. Address before: 230027 No. 96, Jinzhai Road, Anhui, Hefei Patentee before: Hefei Zhongkeda Bio-technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070926 Termination date: 20160905 |